RAPT Therapeutics
RAPT
Market cap $153M

1.16 USD

-0.01

0.85%

At close Apr 2, 4:00 PM EDT

After hours

1.12

-0.04

3.45%

1 day

-0.85%

5 days

-18.88%

1 month

10.48%

3 months

-28.83%

6 months

-48.44%

Year to date

-28.83%

1 year

-85.87%

5 years

-93.79%

10 years

-91.08%

About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Employees: 68

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,398 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

277.24% more ownership

Funds ownership: 85.44% [Q3] → 362.67% (+277.24%) [Q4]

233% more capital invested

Capital invested by funds: $59.9M [Q3] → $199M (+$139M) [Q4]

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

55% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 20

39% more call options, than puts

Call options by funds: $507K | Put options by funds: $365K

4% less funds holding

Funds holding: 94 [Q3] → 90 (-4) [Q4]

13% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 32

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$10

762%

upside

Avg. target

$10

762%

upside

High target

$10

762%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

44% 1-year accuracy

24 / 54 met price target

762%upside

$10

Buy

Reiterated

10 Mar 2025

See Analyst Rankings

Financial journalist opinion

RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March:

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024.

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Zacks Investment Research

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company.

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

RAPT Therapeutics Announces $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of $0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full.

RAPT Therapeutics Announces $150 Million Private Placement

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

On Monday, Rapt Therapeutics, Inc. RAPT stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program.

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and CPI-experienced advanced HNSCC patients.

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Zacks Investment Research

Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround

Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research

Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

See News Rankings

Charts implemented using Lightweight Charts™